PDCD1 and non-small cell lung carcinoma: studied the impact of ATBs on NSCLC, RCC, and urothelial patients who were received anti PD-1/PD-L1 blockade, and they found that progression-free survival (PFS) and overall survival (OS) were significantly shorter in the ATB-treated group, demonstrating that dysbiosis has an impact on therapeutic efficacy of ICIs (20).